Sara M. Tolaney, MD, MPH, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute and member of the Advisory Board for PracticeUpdate Oncology, recommends the following abstracts being presented at this year’s ASCO Annual Meeting, held June 3 through June 7, 2022, in Chicago and simultaneously online.

Clinical Science Symposium: ctDNA: Dawn of a New Era
Saturday, June 4, 2022; 9:00 AM–10:30 EDT

103 Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP). M Lipsyc-Sharf, E De Bruin, K Santos, et al

Oral Abstract Session: Breast Cancer—Metastatic
Saturday, June 4, 2022; 2:15 PM–5:15 PM EDT

LBA1001 Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. HS Rugo, A Bardia, F Marmé, et al

Take-Home Message

• In TROPiCS-02, sacituzumab govitecan compared with standard chemotherapy in metastatic HR-positive breast cancer lead to an improvement in PFS.
• This establishes another new antibody–drug conjugate standard.

1002 Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). IE Krop, N Masuda, T Mukohara, et al

Take-Home Message

• Phase I data from the novel HER3 antibody–drug conjugate patritumab deruxtecan is presented.
• Will this lead to further development of another antibody–drug conjugate with the same payload as T-DXd but a different target?

LBA1003 Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. RS Finn, HS Rugo, VC Dieras, et al

Take-Home Message

• PALOMA-2 will answer if there is an overall survival benefit with palbociclib in a first-line setting.
• To date we have data with ribociclib in this setting with OS benefit but haven’t yet seen mature data on palbociclib or abemaciclib.

LBA1004 A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. K Kalinsky, MK Accordino, C Chiuzan, et al

1007 NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). SJ Chmura, KA Winter, WA Woodward, et al

Plenary Session
Sunday, June 5, 2022; 2:00 PM–5:00 PM EDT

LBA3 Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY Breast04, a randomized, phase 3 study. S Modi, W Jacot, T Yamashita, et al

Take-Home Message

• DESTINY-Breast 04 represents a paradigm shift in breast oncology wherein targeting low expression of a receptor with an antibody–drug conjugate leads to improvements in PFS and OS compared with standard chemotherapy.
• T-DXd will be a new standard of care for metastatic HR-positive HER2-low breast cancer, and we will need to learn how to appropriately test for HER2-low expression to optimize patient selection.

Oral Abstract Session: Breast Cancer—Local/Regional/Adjuvant
Tuesday, June 7, 2022; 10:45 AM–1:45 PM EDT

LBA501 LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). TJ Whelan, S Smith, TO Nielsen, et al

503 Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. L Pusztai, C Denkert, J O'Shaughnessy, et al

Benjamin O. Anderson M.D., Professor of Surgery and Global Health Medicine at the University of Washington and member of the PracticeUpdate Oncology Advisory Board, recommends the following presentations that will be delivered at this year's ASCO Annual Meeting, held June 3 through June 7, 2022, in Chicago and simultaneously online.

Opening Session With the President's Address, Guest Speakers' Address, Presentation of the Fellows of the American Society of Clinical Oncology, and David A. Karnofsky Memorial Award and Lecture
Saturday, June 4, 2022; 10:30 AM–1:00 PM EDT 

Guest Speaker’s Address. AM Ilbawi—WHO

Take-Home Message

• An outstanding perspective on cancer care in low- and middle-income countries. 

Education Session: Tailor-Ax: Personalizing the Treatment of Axilla in Patients With Early-Stage Breast Cancer
Sunday, June 5, 2022; 5:30 PM–6:45 PM EDT 

What Is the Optimal Axillary Management for Early-Stage, Clinical Node–Negative Disease? RA Greenup

Meet the Professors: Disease and Symptom Monitoring After Treatment of Patients With Early-Stage Breast Cancer
Monday, June 6, 2022; 9:00 AM–10:15 AM EDT 

Impact of Treatment on Physical and Psychosocial Aspects of Life. DL Hershman 

Education Session: Can We Afford the Cost of Newly Approved Targeted Therapeutics in the Management of Breast Cancer Globally?
Monday, June 6, 2022; 10:45 AM–12:00 PM EDT 

Breast Cancer Priorities in Low- and Middle-Income Countries. SA Al Sukhun 

Dr. Schwartzberg, Chief of Medical Oncology and Hematology at the Renowned Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno, and Editor-in-Chief of PracticeUpdate Oncology, recommends the following abstracts being presented at this year’s ASCO Annual Meeting, held June 3 through June 7, 2022, in Chicago and simultaneously online. 

EARLY-STAGE BREAST CANCER

Oral Abstract Session: Breast Cancer—Local/Regional/Adjuvant
Tuesday, June 7, 2022; 10:45 AM–1:45 PM EDT

LBA501 LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). TJ Whelan, S Smith, TO Nielsen, et al

503 Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. L Pusztai, C Denkert, J O'Shaughnessy, et al

Take-Home Message

• This exploratory analysis of the KEYNOTE-522 trial assessed event-free survival in terms of residual cancer burden in patients with early TNBC receiving pembrolizumab in addition to chemotherapy. After a median follow-up at 39.1 months (data cutoff), residual cancer burden had eased in those patients randomized to pembrolizumab. Fewer patients in the pembrolizumab arm, than in the placebo arm, across all degrees of residual cancer burden experienced distant recurrence.
• Neoadjuvant pembrolizumab can improve survival in patients with early TNBC. Event-free survival was better in TNBC patients with residual cancer burden receiving pembrolizumab, compared with those randomized to placebo. The higher the degree of residual cancer burden, the worse the event-free survival.

505 Measurement of endocrine activity (SET2,3) related to prognosis and prediction of benefit from dose-dense (DD) chemotherapy in estrogen receptor-positive (ER+) cancer: CALGB 9741 (Alliance). O Metzger, KV Ballman, J Campbell, et al

507 Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial. M Gnant, S Frantal, G Pfeiler, et al

ADVANCED BREAST CANCER 

Oral Abstract Session: Breast Cancer–Metastatic
Saturday, June 4, 2022; 2:15 PM–5:15 PM EDT

1000 Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03. EP Hamilton, VP Bragaia, W Yeo, et al

1002 Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). IE Krop, N Masuda, T Mukohara, et al

Take-Home Message

• Phase I data from the novel HER3 antibody–drug conjugate patritumab deruxtecan is presented.
• Possibly this is a new type of treatment; will it lead to further development of another antibody–drug conjugate with the same payload as T-DXd but a different target?

LBA1001 Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. HS Rugo, A Bardia, F Marmé, et al

LBA1003 Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. RS Finn, HS Rugo, VC Dieras, et al

Take-Home Message

• PALOMA-2 will answer if there is an overall survival benefit with palbociclib in a first-line setting.
• To date we have data with ribociclib in this setting with an overall survival benefit but haven’t yet seen mature data on palbociclib or abemaciclib.

LBA1004 A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. K Kalinsky, MK Accordino, C Chiuzan, et al

1007 NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). SJ Chmura, KA Winter, WA Woodward, et al

Plenary Session: Breast Cancer-Local/Regional/Adjuvant
Sunday, June 5, 2022; 2:00 PM – 5:00 PM EDT 

LBA3 Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY Breast04, a randomized, phase 3 study. S Modi, W Jacot, T Yamashita, et al

Take-Home Message

• DESTINY-Breast 04 represents a paradigm shift in breast oncology wherein targeting low expression of a receptor with an antibody–drug conjugate leads to improvements in PFS and OS compared with standard chemotherapy.

• Trastuzumab deruxtecan will be a new standard of care for metastatic HR-positive, HER2-low breast cancer, and we will need to learn how to appropriately test for HER2-low expression to optimize patient selection.

Dr. Reshma Mahtani, Chief of Breast Medical Oncology at the Miami Cancer Institute, and an Associate Editor of the PracticeUpdate Center of Excellence for Metastatic Breast Cancer, recommends the following abstracts being presented at this year’s ASCO Annual Meeting, held June 3 through June 7, 2022, in Chicago and simultaneously online. 

Oral Abstract Session: Breast Cancer–Metastatic
Saturday, June 4, 2022; 2:15 PM–5:15 PM EDT

LBA1001 Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. HS Rugo, A Bardia, F Marmé, et al

Take-Home Message

• In TROPiCS-02, sacituzumab govitecan compared with standard chemotherapy in metastatic HR-positive breast cancer led to an improvement in PFS.
• This establishes another new antibody–drug conjugate standard.

LBA1003 Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. RS Finn, HS Rugo, VC Dieras, et al

Take-Home Message

• PALOMA-2 will answer if there is an overall survival benefit with palbociclib in a first-line setting.
• To date we have data with ribociclib in this setting with an overall survival benefit but haven’t yet seen mature data on palbociclib or abemaciclib.

LBA1004 A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. K Kalinsky, MK Accordino, C Chiuzan, et al

1007 NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). SJ Chmura, KA Winter, WA Woodward, et al

Plenary Session
Sunday, June 5, 2022; 2:00 PM–5:00 PM EDT

LBA3 Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY Breast04, a randomized, phase 3 study. S Modi, W Jacot, T Yamashita, et al

Take-Home Message

• DESTINY-Breast 04 represents a paradigm shift in breast oncology wherein targeting low expression of a receptor with an antibody–drug conjugate leads to improvements in PFS and OS compared with standard chemotherapy.
• Trastuzumab deruxtecan will be a new standard of care for metastatic HR-positive, HER2-low breast cancer, and we will need to learn how to appropriately test for HER2-low expression to optimize patient selection.

Poster Discussion Session: Breast Cancer—Metastatic
Monday, June 6, 2022; 12:30 PM–2:00 PM EDT

1015 Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC). HS Rugo, J O'Shaughnessy, KL Jhaveri, et al

Poster Discussion Session: Breast Cancer—Local/Regional/Adjuvant
Monday, June 6, 2022; 2:15 PM–3:45 PM EDT

513 Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT). P Sharma, SR Stecklein, R Yoder, et al

515 Racial/ethnic disparities in locoregional recurrence in hormone-receptor positive node-negative breast cancer patients enrolled in the TAILORx trial. O Kantor, TA King, RA Freedman, et al

Oral Abstract Session: Breast Cancer—Local/Regional/Adjuvant
Tuesday, June 7, 2022; 10:45 AM–1:45 PM EDT

503 Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. L Pusztai, C Denkert, J O'Shaughnessy, et al

505 Measurement of endocrine activity (SET2,3) related to prognosis and prediction of benefit from dose-dense (DD) chemotherapy in estrogen receptor-positive (ER+) cancer: CALGB 9741 (Alliance). O Metzger, KV Ballman, J Campbell, et al

25 juni 2022: Aanbevolen door Professor Lillie Shockney, Associate Editor of the PracticeUpdate Center of Excellence Metastatic Breast Cancer, recommends the following abstracts being presented at this year’s ASCO Annual Meeting, held June 3 through June 7, 2022, in Chicago and simultaneously online.  

Poster Session: Breast Cancer—Metastatic
Publication Only

JN Krokhmal, LY Rozenko, EM Frantsiyants, et al

Take-Home Message

• Some patients with ER+/HER− disease are diagnosed with bone metastases many years later, even 2 decades after completing their original treatment. However, they likely have been harboring evidence; if a bone scan had been done, the metastases could have been found much sooner. The question then is if it is better to leave things alone and wait for physical symptoms before we do a staging workup.
• Some patients have said they were glad they didn't know they had metastases because it gave them 10 years of feeling good and not worrying. Others have wondered if their disease, limited to the bones, could have been treated earlier.

Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sunday, June 5, 2022; Starting at 9:00 AM EDT

3055 Defining resistance mechanisms to CDK4/6 inhibition in hormone receptor-positive HER2-negative metastatic breast cancer (MBC) through a machine learning approach applied to circulating tumor DNA (ctDNA). L Gerratana, C Reduzzi, AA Davis, et al

Poster Session: Breast Cancer—Metastatic
Monday, June 6, 2022; Starting at 9:00 AM EDT

1044 Prognostic implications of HER2Neu-low in metastatic breast cancer. S Hasan, Z Neubauer, RH Press, et al

Take-Home Message

• HER2 testing has been challenging from the outset. Having to do multiple tests to figure out if the cancer is HER2-positive or HER2-negative has always been confusing to patients.
• In the way that hormone receptors are "slightly positive," should we more aggressively treat disease that has some degree of HER2 positivity? 

1047 Factors associated with short- and long-term survival in metastatic HER2+ breast cancer. JP Leone, J Leone, CT Vallejo, et al 

1099 Is cure possible for breast cancer metastatic to the liver? R Adam, D Badrudin, MA Allard, et al

1106 Optimal timing and interval of imaging for metastatic breast cancer. SR Patel, H Itakura, GW Sledge Jr

Poster Discussion Session: Breast Cancer—Metastatic
Monday, June 6, 2022; Starting at 12:30 PM EDT

1013 Effect of socioeconomic status as measured by Neighborhood Deprivation Index on survival in metastatic breast cancer. SP Narayanan, MQ Rosenzweig, et al

Take-Home Message

• Where someone lives shouldn't determine the likelihood that she will die of breast cancer. We know, however, that health disparities associated with socioeconomic status, geography, education level, unemployment, and other factors can lead to higher stage of breast cancer at diagnosis and greater likelihood that a woman will die from the disease.
• The needs in vulnerable communities is great, and easy access to government grants can result in better community outreach and successful partnerships with community leaders to bring women in for mammography screening and education, while also providing navigation services so that women are diagnosed earlier and have a better shot at survival.

ASCO 2022, aanbevolen abstracten borstkanker

---

• ASCO 2023: aanbevolen abstracten voor borstkanker van vooraanstaande oncologen wereldwijd

---

• ASCO 2022: aanbevolen abstracten voor borstkanker van Sara M. Tolaney, MD, MPH, LEE SCHWARTZBERG, MD, FACP en Dr. Benjamin Andersen

---

• ASCO 2021: aanbevolen abstracten specifiek gerelateerd aan borstkanker

---

• ASCO 2020: Aanbevolen abstracten specifiek voor borstkanker in alle stadia en zowel hormoongerelateerd als triple negatief

---

• Aanbevolen abstracten voor borstkanker van ASCO 2019

---

• ASCO 2018 Recente studiepublicaties over borstkanker

---

• Belangrijke abstracten van ASCO 2018 gerelateerd aan borstkanker

---

• ASCO 2024: aanbevolen abstracten gerelateerd aan borstkanker door vooraanstaande oncologen wereldwijd